Letter to the editor: 'Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa'.

IF 2.7 3区医学 Q2 PHARMACOLOGY & PHARMACY Expert Opinion on Emerging Drugs Pub Date : 2022-12-01 DOI:10.1080/14728214.2022.2152202

Anastasios Georgiadis, Alexander J Smith, Michel Michaelides, Stuart Naylor, Alexandria Forbes

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

致编辑的信:“rpcr相关x连锁视网膜色素变性的新兴基因治疗产品”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Opinion on Emerging Drugs 医学-药学

CiteScore

5.90

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Expert Opinion on Emerging Drugs (ISSN 1472-8214 [print], 1744-7623 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing structured reviews on Phase II and Phase III drugs/drug classes emerging onto the market across all therapy areas, providing expert opinion on their potential impact on the current management of specific diseases.

期刊最新文献

Emerging treatments for sarcoma: from 2024 onward. Emerging biological treatments for asthma. Mitapivat: a step forward across different hemolytic diseases. FcRn inhibitors in the context of myasthenia gravis. Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?